American Journal of Medical Case Reports
ISSN (Print): 2374-2151 ISSN (Online): 2374-216X Website: http://www.sciepub.com/journal/ajmcr Editor-in-chief: Samy, I. McFarlane
Open Access
Journal Browser
Go
American Journal of Medical Case Reports. 2015, 3(4), 98-101
DOI: 10.12691/ajmcr-3-4-3
Open AccessCase Report

Malignant Peritoneal Mesothelioma Presenting as Ascites of Unknown Origin

Sze Li Siow1, and Hans Alexander Mahendran1

1Department of Surgery, Sarawak General Hospital, Malaysia

Pub. Date: March 01, 2015

Cite this paper:
Sze Li Siow and Hans Alexander Mahendran. Malignant Peritoneal Mesothelioma Presenting as Ascites of Unknown Origin. American Journal of Medical Case Reports. 2015; 3(4):98-101. doi: 10.12691/ajmcr-3-4-3

Abstract

Malignant mesothelioma is a rare but highly aggressive and fatal tumour arising from the mesothelial cells, which is associated with an involvement of the peritoneum in 30% of cases. We report a 48-year-old man with malignant peritoneal mesothelioma who presented with ascites of unknown origin, and discussed the clinical presentation, investigation and management, as well as the diagnostic difficulties in managing this unusual and unfortunate case.

Keywords:
Mesothelioma peritoneal mesothelioma ascites

Creative CommonsThis work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References:

[1]  Papiris SA, Roussos C. Epidemiology and Etiology of Mesothelioma. In: Syrigos KN, Nutting CM, Roussos C, eds. Tumors of the Chest, Berlin Heidelberg: Springer, 2006: 473-480.
 
[2]  Chua TC, Yan TD, Morris DL. Peritoneal mesothelioma: current understanding and management. Can J Surg 2009; 52: 59-64.
 
[3]  Chahinian AP, Pajak TF, Holland JF, Norton L, Ambinder RM, Mandel EM. Diffuse malignant mesothelioma. Prospective evaluation of 69 patients. Ann Intern Med 1982; 96: 746-55.
 
[4]  Weiner SJ, Miandoab. Pathogenesis of malignant pleural mesothelioma and the role of environmental and genetic factors. J Cancer Res Clin Oncol 2009; 135: 15-27.
 
[5]  Husain AN, Colby TV, Ordonez NG, Krausz T, Borczuk A, Cagle PT, et al. Guidelines for pathologic diagnosis of malignant mesothelioma: a consensus statement from the International Mesothelioma Interest Group. Arch Pathol Lab Med 2009; 133: 1317-1331.
 
[6]  Acherman YTZ, Welch LS, Bromley CM, Sugarbaker PH. Clinical presentation of peritoneal mesothelioma. Tumori 2003; 89: 269-73.
 
[7]  Yan TD, Haveric N, Carmignani CP, Bromley CM, Sugarbaker PH. Computed tomographic characterization of malignant peritoneal mesothelioma. Tumori 2005; 91: 394-400.
 
[8]  Bridda A, Padoan I, Mencarelli R, Frego M. Peritoneal Mesothelioma: A Review. MedGenMed 2007; 9: 32.
 
[9]  Turner KM, Varghese S, Alexander HR. Surgery for peritoneal mesothelioma. Curr Treat Options Oncol 2011; 12: 189-200.
 
[10]  Park BJ, Alexander HR, Libutti SK, Wu P, Royalty D, Kranda KC, et al. Treatment of primary peritoneal mesothelioma by continuous hyperthermic peritoneal perfusion (CHPP). Ann Surg Oncol 1999; 6: 582-590.
 
[11]  Yan TD, Welch L, Black D, Sugarbaker PH. A systematic review on the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for diffuse malignancy peritoneal mesothelioma. Ann Oncol 2007; 18:827-34.
 
[12]  Alexander HR, Fraker DL. Continuos hyperthermic peritoneal perfusion with cisplatin in the treatment of peritoneal carcinomatosis. Reg Cancer Treat 1995; 8: 2-7.
 
[13]  Yan TD, Edwards G, Alderman R, Marquardt CE, Sugarbaker PH. Morbidity and mortality assessment of cytoreductive surgery and perioperative intraperitoneal chemotherapy for diffuse malignant peritoneal mesothelioma- a prospective study of 70 consecutive cases. Ann Surg Oncol 2007; 14: 515-25.
 
[14]  Castagneto B, Botta M, Aitini E, Spigno F, Degiovanni D, Alabiso O, et al. Phase II study of pemetrexed in combination with carboplatin in patients with malignant pleural mesothelioma (MPM). Ann Oncol 2008; 19: 370-3.
 
[15]  Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003; 21: 2636-44.
 
[16]  Fennell DA, Gaudino G, O’Byrne KJ, Mutti L, van Meerbeeck J. Advances in the systemic therapy of malignant pleural mesothelioma. Nat Clin Pract Oncol 2008; 5:136-47.
 
[17]  Kikuchi Y, Watanabe T, Igarashi Y, Sumino Y, Tsuboi K. The chemotherapy of peritoneal malignant mesothelioma. Gan To Kagaku Ryoho 2012; 39: 718-721.
 
[18]  Mott FE. Mesothelioma: A Review. The Ochsner Journal 2012; 12: 70-79.